Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study
| Autor: | Ranjan Pathak, Smith Giri, Vijaya Raj Bhatt, Nabin Khanal, Valerie Shostrom, Smrity Upadhyay |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
Pediatrics medicine.medical_specialty education.field_of_study business.industry Incidence (epidemiology) Population Absolute risk reduction Retrospective cohort study Hematology medicine.disease 03 medical and health sciences 0302 clinical medicine Polycythemia vera Standardized mortality ratio Oncology 030220 oncology & carcinogenesis Cohort medicine Cumulative incidence education business 030215 immunology |
| Zdroj: | Leukemia & Lymphoma. 57:129-133 |
| ISSN: | 1029-2403 1042-8194 |
| DOI: | 10.3109/10428194.2015.1071492 |
| Popis: | Although the median survival in polycythemia vera (PV) is 14 years, mortality is higher than in an age- and sex-matched population. This study included 3941 PV patients diagnosed between 2000–2012 from Surveillance, Epidemiology and End Results (SEER) 13 registry to determine 5-year survival and the incidence of second primary malignancies (SPM). The actuarial 5 year survival in the overall cohort was 79.5%. The cumulative incidence of SPM was 13.1% at 10 years. SPMs occurred at a standardized incidence ratio (SIR) of 1.29 (95% CI = 1.16–1.43; p < 0.001) with an absolute excess risk (AER) of 42.49 per 10 000 population. A significantly higher risk was noted for acute myeloid leukemia (SIR = 12.24; 95% CI = 8.17–17.8; p-value < 0.001) and chronic myeloid leukemia (SIR = 10.66; 95% CI = 3.75–19.6; p-value < 0.001). Patients with PV are at a high risk of SPM and leukemic transformation, which may compromise long-term survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|